secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOGEN INC. (BIIB)
CIK:        0000875045
Form:       8-K
Filed at:   2023-07-31T23:59:59+00:00
Accession:  0001193125-23-198542
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biogen to acquire Reata Pharmaceuticals for $172.50 per share in cash
---------------------------------------------------------------------

- Acquisition of Reata for $172.50 per share cash; Reata board unanimously approved.
- Biogen obtained $1.5B bridge loan commitment from JPMorgan to help finance the deal.
- Transaction expected to close by Jan 28, 2024, subject to Reata stockholder approval and regulatory clearances.
- Termination fees: $264M payable by Reata (if it terminates for a superior proposal) and $301M payable by Biogen.
- Support agreements with certain Reata stockholders to vote shares in favor of the merger.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875045/000119312523198542/0001193125-23-198542-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875045/000119312523198542/d454539d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-198542

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer